Medy-Tox Income Statement

Financials in millions KRW. Fiscal year is January - December.

Millions KRW. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Operating Revenue	241,797	228,622	221,121	195,096	184,870	140,828
Other Revenue	-	-	-	-0	-0	-
Revenue	241,797	228,622	221,121	195,096	184,870	140,828
Revenue Growth (YoY)	0.14%	3.39%	13.34%	5.53%	31.27%	-31.60%
Cost of Revenue	101,984	90,038	87,625	69,048	79,397	66,928
Gross Profit	139,813	138,584	133,496	126,048	105,473	73,900
Selling, General & Admin	78,308	78,370	86,605	47,679	41,938	59,544
Research & Development	29,821	29,821	25,133	23,324	23,267	32,544
Amortization of Goodwill & Intangibles	2,282	2,282	1,284	799.22	834.58	662.42
Other Operating Expenses	1,346	1,346	1,322	1,242	1,216	1,403
Operating Expenses	118,174	118,236	116,173	79,383	72,335	110,969
Operating Income	21,639	20,349	17,322	46,665	33,138	-37,070
Interest Expense	-1,727	-1,727	-2,333	-2,314	-4,781	-4,176
Interest & Investment Income	925.15	925.15	896.43	610.76	957.22	340.02
Earnings From Equity Investments	6,675	5,877	1,363	5,129	-1,456	-2,432
Currency Exchange Gain (Loss)	4,387	4,387	475.22	3,425	2,111	-376.81
Other Non Operating Income (Expenses)	-2,470	-4,138	-605.87	-715.84	108,431	6,967
EBT Excluding Unusual Items	29,430	25,673	17,118	52,800	138,400	-36,748
Impairment of Goodwill	-	-	-	-	-	-711.12
Gain (Loss) on Sale of Investments	126.49	126.49	-593.36	-3,044	2,666	-1,067
Gain (Loss) on Sale of Assets	323.58	323.58	-671.97	-230.42	131.48	58.63
Asset Writedown	-8,624	-8,624	-	-	-12,932	-3,671
Pretax Income	21,256	17,499	15,853	49,526	128,265	-42,139
Income Tax Expense	112.04	1,425	6,163	12,930	35,003	-12,100
Earnings From Continuing Operations	21,144	16,074	9,690	36,596	93,263	-30,039
Minority Interest in Earnings	1,673	881.22	65.28	414.16	891.27	462.11
Net Income	22,817	16,955	9,755	37,010	94,154	-29,577
Preferred Dividends & Other Adjustments	975	975	975	975.33	974.73	0.7
Net Income to Common	21,842	15,980	8,780	36,035	93,179	-29,577
Net Income Growth	94.98%	73.81%	-73.64%	-60.69%	-	-
Shares Outstanding (Basic)	6	7	7	7	6	6
Shares Outstanding (Diluted)	6	7	7	7	6	6
Shares Change (YoY)	-3.59%	0.40%	2.02%	2.28%	0.04%	-0.82%
EPS (Basic)	3398.79	2376.57	1311.06	5491.68	14587.59	-4609.95
EPS (Diluted)	3398.79	2376.57	1311.00	5489.34	14517.37	-4610.30
EPS Growth	111.21%	81.28%	-76.12%	-62.19%	-	-
Free Cash Flow	53,668	27,830	5,862	16,304	2,452	-13,217
Free Cash Flow Per Share	8351.16	4138.95	875.31	2483.66	382.01	-2059.99
Dividend Per Share	1200.000	1100.000	-	-	-	-
Gross Margin	57.82%	60.62%	60.37%	64.61%	57.05%	52.48%
Operating Margin	8.95%	8.90%	7.83%	23.92%	17.93%	-26.32%
Profit Margin	9.03%	6.99%	3.97%	18.47%	50.40%	-21.00%
Free Cash Flow Margin	22.20%	12.17%	2.65%	8.36%	1.33%	-9.38%
EBITDA	41,815	40,307	32,698	61,766	51,394	-18,472
EBITDA Margin	17.29%	17.63%	14.79%	31.66%	27.80%	-13.12%
D&A For EBITDA	20,176	19,959	15,376	15,101	18,256	18,597
EBIT	21,639	20,349	17,322	46,665	33,138	-37,070
EBIT Margin	8.95%	8.90%	7.83%	23.92%	17.93%	-26.32%
Effective Tax Rate	0.53%	8.15%	38.88%	26.11%	27.29%	-
Advertising Expenses	-	7,146	5,976	3,351	2,031	3,839

Source: S&P Global Market Intelligence. Standard template. Financial Sources.